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The Pancreas group is connected to Section of Gastro and Nutrition and the Bergen 
Research Group for Ultrasound in Gastroenterology (BRUSE) at Department of 
Clinical Medicine, University of Bergen. This research milieu has served as a 
stimulating environment for this dissertation. BRUSE is working to develop and 
validate new methods for clinical ultrasonography, with the goal of improving patient 
care and treatment.  The Gastro Section is continuously working to improve basic and 
clinical methods for pancreatic diseases. BRUSE is internationally recognized as 
pioneers in both transabdominal and endoscopic ultrasound and has a broad 
international collaboration. Altogether 19 PhD dissertations plus 10 ongoing, 6 books 
and over 300 research publications have emerged from this research group in Bergen.  
National Centre for Ultrasound in Gastroenterology (NCUG) was established at 
Haukeland University Hospital by the National Health Authorities in 2001 as a national 
service of excellent competence. NCUG is a leading international ultrasound centre 
and was in 2014 accredited as a European Learning Centre. 
The research has been performed in cooperation with Medical Department, Voss 
Hospital and the Paediatric Department. Regular and valuable cooperation has also 
been performed with the Pancreas group at Aalborg University, Denmark.   
 






It was an honour to be elected as the first partner from the very beginning to a 
continuously growing scientific environment, “The Bergen Pancreatic Club”. The 
enormous engagement of my main supervisor motivated me to study pancreas 
function testing in all its facets in our clinic, a hallmark in updated diagnostic 
procedures in chronic pancreatitis.  
First, I want to thank my main supervisor Professor PhD MD Georg Dimcevski for 
extraordinary help. Planning, organizing and performing all projects were not 
possible without his enormous energy and authority. There was no obstacle, which 
could not be eluded. His humour, experience and pragmatism were irreplaceable in 
futile situations. Without my co-supervisor Professor PhD MD Odd Helge Gilja, it 
was not possible to be accepted as a non-funded PhD candidate at the University of 
Bergen and simultaneously working as external clinician. His overall competence and 
experience in leadership was the guarantee to perform this work. Especially help in 
establishing ultrasound in our project is his merit. The other co-supervisor Professor 
Trygve Hausken encouraged me in 2004 to reintroduce scientific work, 14 years after 
a German doctor degree.  
MD Trond Engjom is a central person in this work. As we shared aspects of the same 
task, articles were prepared very closely, cooperation in project planning and 
interpretation of data was perfect. His critical review augmented the quality of 
presentations, posters and articles fundamentally.   
PhD, MD Erling Tjora also participated in the pancreas project at an early stage. He 
contributed essentially with the measurement of enzymes in duodenal juice and 
broadened the knowledge of Diabetes type III in our group. 
Professor Lage Aksnes provided generously his laboratory facilities and helped to 
establish enzyme analyses in duodenal juice. Sadly, he died suddenly and left behind 
an irrecoverable gap.   
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PhD Oddrun Gudbrandsen became interested in pancreas function testing when we 
cooperated as supervisors for master students in nutrition. With her, we could 
establish automation of measuring bicarbonate, Amylase and Lipase in duodenal 
juice in the clinical repertoire. 
It was generous of my former teacher and mentor Professor Arnold Berstad to reveal 
the secrets of measuring faecal fat after the method of van de Kamer. As this method 
was performed modified over decades at our clinic, we studied together its accuracy. 
In this project, I was lucky to meet senior bioengineer Aud Sissel Hjartholm-Eriksen. 
She performed back titration of bicarbonate in duodenal juice with high accuracy and 
worked extraordinary exactly.  
Liv Aasmul, senior bioengineer was irreplaceable from the first endoscopic secretin 
test. She prepared duodenal juice in the endoscopic unit before analyses. Her help 
with maintenance of the patient database was magnificent. 
PhD MD Roald Flesland Havre performed EUS of the pancreas virtuously. He 
established the routine of Rosemont scoring in patients with symptoms suspicious for 
chronic pancreatitis; if necessary interventions were performed immediately. 
Advanced diagnostic and therapeutic endoscopic interventions were not possible 
without high skilled endoscopist Khanh Do-Cong Pham. 
Great thanks to the staff at the endoscopic unit with their positive and open mind and 
helpfulness. 
I was happy that the CEO of Voss Hospital Rolf Abrahamsen, and the leader of 
Medical Department Anita Spikkeland provided for the first time the possibility to 
work additionally as a PhD candidate. The flexibility and support of my working 
colleagues was remarkable. 
The importance of a family cannot be underestimated. My wife Esther and my 
children Vera, Rebecca and Noah tolerated my life as commuter well and patiently. 
When at home, they answered my absence of mind with a knowing smile.  Thus, we 
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CP:      Chronic pancreatitis 
EUS:      Endosonographic Ultrasonography 
CT:     Computed Tomography 
MRI:     Magnetic Resonance Imaging 
ERCP:    Endoscopic Retrograde Cholangiography 
MRCP:    Magnetic Resonance Cholangio-Pancreaticography  
EST:     Endoscopic Secretin Test 
FE1:     Faecal Elastase 1 
MOPS:    3-(N-morpholino) propanesulfonic acid 
BSA:     Bovine serum albumin 
EPI:     Exocrine Pancreatic Insufficiency 
CCK:     Cholecystokinin 
PRSS1:    Protease, Serine 1 
SPINK:    Serine Protease Inhibitor Kazal-type 1 
CFTR:  Cystic fibrosis transmembrane conductance 
regulator 
CTRC: Chymotrypsin C 





The diagnoses of chronic pancreatitis (CP) may range from a simple and straight 
forward task to a tremendously challenging and intensive investigative process. The 
most important exogenous risk factors are alcohol consumption and smoking. 
Genetics, anatomical variants and biliary diseases are also important. One risk factor 
alone or in combination with others gives different morphological and functional 
changes. Prediction of clinical outcome is dubious, and the range is broad, from 
asymptomatic via mild to severe disease manifestations.   
Pancreatic function is of importance, as it may be key for early diagnoses of CP. 
Therapy of pancreatic failure at an early state can prevent complications as weight 
loss, deleterious nutritional state and increased mortality.  
Direct pancreas function testing is worldwide rarely used in clinical practice as it is 
cumbersome, not standardized, and needs a broad clinical infrastructure. 
In our opinion, with this work, we have substantially simplified the endoscopic 
procedure, analyses of bicarbonate and enzymes in duodenal juice. Thus, the practical 
performance of direct pancreas function testing is possible in any clinical unit with 
basic endoscopic and laboratory services. 
This thesis describes a clinical approach to simplify diagnostics of CP with 








The diagnosis of CP is not yet clearly defined. Many national guidelines exist, but - 
as in many other not clearly defined diseases - there is no worldwide consensus. In 
CP, evaluation of exocrine pancreatic function is crucial because symptoms are often 
diffuse and overlooked by the doctors. Additionally, early diagnosis of exocrine 
pancreatic failure is important as its consequence, malnutrition and commonly 
abdominal pain, leads to serious complications and reduced life expectancy. Direct 




The main aim was to develop and establish a multimodal algorithm for the diagnoses 
of CP, accurate and easy to handle in clinical practice. Secondary, we wanted to 
simplify direct pancreas function testing including a): the performance of a short 
endoscopic test (article I) and b): the analyses of ingredients in duodenal juice by 
automation: bicarbonate (article II), Amylase (article III) and Lipase (article IV).  
 
Materials and Methods:  
We examined consecutively healthy controls and patients referred to our outpatient 
clinic due to symptoms suspicious of CP.  We assessed patients with a modified 
Layer (Mayo) score, which includes imaging, pancreas function testing and medical 
history. We established a short endoscopic secretin test and analysed bicarbonate, 
Amylase and Lipase in duodenal juice as markers for ductal and acinar exocrine 
pancreatic function. In article I, we determined sensitivity, specificity and accuracy of 
bicarbonate and faecal-elastase, using our modified secretin-stimulated upper 
endoscopy (short endoscopic secretin test, or EST).  In article II, III, IV, we describe 
correlation between automation of analyses of Bicarbonate, Amylase and Lipase in 




I. Short endoscopic secretin test: Fifty-two patients aged 19 to 67 years and 25 
healthy controls aged 19 to 64 years were included. Twenty-four patients fulfilled the 
modified Layer score for CP or non-CP. The overall accuracy of the EST versus FE1 
test was 85%/71%, with positive and negative predictive values of 100%/79% and 
80%/69%, respectively. 
II. Automation of bicarbonate measurement: 177 samples from 71 patients were 
analysed. Correlation coefficient of all measurements was r = 0.98 (p < 0.001). 
Correlation coefficient of fresh versus frozen samples conducted with automatic 
spectrophotometry (n = 25): r = 0.96 (p < 0.001).  
III. Automation of amylase measurement: We analysed 52 samples for assay of 
amylase in pairs. Correlation between measurements with the two methods was r = 
0.99 (p<0.001).  
IV. Automation of lipase measurement: We tested stability of 54 samples from 21 
patients. Diluting samples with MOPS buffer, added BSA gave stable results, and 
was superior to diluting samples in saline. We compared the two assays in 50 samples 




I: Short EST is rapid and easy to perform and can be incorporated in daily routine in 
every clinical endoscopic unit. EST is superior to FE1 in the assessment of pancreatic 
insufficiency, leading to earlier diagnosis of moderate and early or mild CP. 
II: The measurement of bicarbonate in fresh and thawed samples by automatic 
spectrophotometric analysis correlates excellent with the back-titration gold standard.  
III and IV: Quantification of duodenal amylase and lipase activity with automated 
spectrophotometry has excellent correlation to measurements made by the manual 
methods.  
Overall, Endoscopic secretin test is easy to perform, and can be incorporated in a 
diagnostic endoscopic examination. Automated measurement of bicarbonate, lipase 
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and amylase in duodenal juice simplifies the analytical methods and shortens time 
from test to result substantially. Standardized, centre-independent analyses of 
duodenal juice with quantification of ductal and acinar function in any unit with basic 




List of Publications 
Erchinger F, Engjom T, Tjora E, Hoem D, Hausken T, Gilja OH, Dimcevski G. 
"Quantification of pancreatic function using a clinically feasible short endoscopic secretin 
test.” Pancreas. 2013 Oct; 42(7):1101-6. 
 
Erchinger F, Engjom T, Gudbrandsen OA, Tjora E, Gilja OH, Dimcevski G. 
“Automated spectrophotometric bicarbonate analysis in duodenal juice compared to the back 
titration method.” Pancreatology. 2016 Mar-Apr; 16(2):231-7. 
 
Erchinger F, Engjom T, Tjora E, Aksnes L, Dimcevski G, Gudbrandsen OA. “Analysis of 
amylase in duodenal juice - Automated kinetic spectrophotometric analysis versus manual 
colorimetric endpoint assay” Pancreatology. 2017 Mar - Apr;17(2):182-187. 
 
Tjora E, Erchinger F, Engjom T, Aksnes L, Dimcevski G, Gudbrandsen OA. “Analysis of 
Lipase in duodenal juice Automated kinetic spectrophotometric analysis versus manual 




















Contents             Page 
Scientific environment         3 
Acknowledgements         4 
Abbreviations          7 
Preface           8 
Abstract           9 
List of Publications               12 
1. Introduction               14 
2. Aims of this work               42 
3. Methodological aspects             45 
4. Main results               49 
5. Discussion                51 
6. Conclusions               57 
7. Future Perspectives              58 
References                61 






In the western world the pancreas was first described by the Greek anatomist and 
surgeon Herophilus of Chalcedon ( b. 336 B.C.)(1). The first documentation of the 
pancreas accepted as anatomical term was in 100 A.D.  (Ruphus of Ephesus, Greek 
anatomist and surgeon)(2;3). It consists of two words: Pan = all and Kreas = flesh, 
meaning an organ without bone or cartilage. In the 17th century Johan Georg Wirsung 
described the main pancreatic duct as an anatomical structure(4). More than 100 
years later, Thomas Sömmering was the first describing its function by using the 
word abdominal salivary gland (Bauchspeicheldrüse)(5).  
 
Samuel Thomas von Sömmerring. Portrait by Karl Thelott (1793–1830) - Dr. Senckenbergische 
Stiftung, Nibelungenallee 37 – 41, Frankfurt am Main, Germany; open source 
In 1812 Johann Friedrich Meckel recognized the connection between embryology and 
pancreas divisum, including the accessory duct and sphincter discovered by 
Santorini(6;7). 
Fundamentals of embryology  
One month after gestation, a ventral and dorsal bud is present. After rotation of the 
ventral pancreas and the bile duct the two parts fusion, the duodenum gets in ventral 
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position. The ventral pancreas gets the ventrale Anlage (dorsal part of the caput) and 
uncinate process. The dorsale Anlage forms the ventral part of the caput, the corpus 
and the cauda(8). 
 
From: Pancreatic Embryology and Development; The Exocrine Pancreas. Pandol SJ. San Rafael 
(CA): Morgan & Claypool Life Sciences; 2010; open source 
If the two parts of the pancreas do not fusion, various variants of the duct system 
exist. This is called pancreas divisum (9). Mostly, it is an incidental finding in 
asymptomatic subjects, but pancreas divisum can also be the source of relapsing 
acute pancreatitis especially in combination with chromosomal aberrations. 
Anatomy 
The pancreas is the most central organ in our body; it is half way in the longitudinal, 
sagittal and transversal plain. The neck is an important landmark as the superior and 
inferior mesenteric vein fusion to the portal vein at this place. Measures have a wide 
range, from 80-100 g in weight, 14 to 18 cm in length, 2 to 9 cm width and 2 to 3 cm 
thickness. Head, neck, body and tail form the whole organ. It mainly consists of water 
(71%), protein (13%) and fat (3-20%).The pancreas is also the most veiled organ 
because of its retroperitoneal position and neighbourhood to many other organs: 
Stomach, duodenum, liver, gallbladder, biliary tree, aorta and celiac trunk, vena cava, 
colon, kidneys and spleen. This may be the reason of complex arterial, venous and 
lymph supply with many anastomoses. Veins from the enteral drainage supply also 
the pancreas and complete the enteropancreatic circle. Pancreatic ducts drain 
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pancreatic juice to the duodenum, and the main pancreatic duct joins with the main 
biliary duct proximal the papilla of Vater. The small glandular parts are forming the 
exocrine and endocrine pancreas. The exocrine part consists of the ducts and the 
acini. Both subdivisions have its own functions: the ducts transport enzymes and 
proenzymes (zymogenes), to nutrition parts in the duodenum. The centro acinar cells 
produce bicarbonate, water, sodium, potassium and calcium, the acinar cells lipase, 
amylase, nucleases, trypsinogen, chymotrypsinogen, proelastase and propeptidase 
A/B(10). The endocrine pancreas transports hormones in the blood vessels. It consists 
of Langerhans islets. Its cells produce Insulin (beta cells; 68%), glucagon (alpha cells; 
20%), somatostatin (delta cells, 10%) and pancreatic polypeptide (pp cells; 2%).   
Both parts of the autonomous nerve system, the sympathetic and parasympathetic 
nerves, but also visceral afferent nerves affect the pancreas. 
 
From: Pandol, Stephen J. (2015). Normal Pancreatic Function. Pancreapedia: Exocrine Pancreas 
Knowledge Base. Open source 
The acini  are surrounded by nerve bundles and each single acinus is innervated by its 
own fibre(11). In this setting the muscarinic nerve system is of importance 
considering pancreatic enzyme secretion(12;13).   
Physiology 
The pancreas is important for metabolism and produces hormones and digestive juice. 
The interplay between, nerves and hormones with other organs, structures and cells is 
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multifarious and complex(14). Importantly, most basic physiology is based on studies 
with animals and not humans(15). Therefore, cautious interpretation of former basic 
research is recommended. For example, rats have no gallbladder. Thus, bile acids and 
salts are not as concentrated in the duodenum as in humans. This may have 
consequences to fat absorption(16). 
Pavlov saw that acid chyme entering the duodenum provoked secretion of pancreatic 
juice; additionally he demonstrated that different food composition caused 
differences in metabolic capabilities of pancreatic juice, peptic when feeding with 
meat, lipolytic when feeding with fat and amylolytic when feeding with 
carbohydrates(17).  
Starling described in 1902 the first hormone secretin, a very potent stimulator of 
pancreatic secretion(17). He concluded that the role of the autonomous nerve system 
is not as strong as the hormonal mechanism; the afferent vagus nerve delivers 
olfactory, gustatory, gastric and intestinal signals to the dorsal motor nucleus of the 
vagus nerve which stimulates exocrine pancreatic function(18).   
The sympathetic nerve in the paraganglia inhibits pancreatic exocrine secretion 
indirectly by reducing blood flow. After ingestion of fat and protein, secretion of 
cholecystokinin begins. It provokes contraction of the gall bladder, relaxation of 
sphincter of Oddi, delayed gastric emptying and satiety. The role as a secretagogue of 
pancreatic juice is marginal (19-21). This is controversial to old dogmas, which 
described CCK as only strong hormonal stimulator for acinar cells. Later literature 
describes the strong effect of CCK to enzyme delivery out of the acini as a paracrine 
effect, as it provokes vago-vagal enteropancreatic reflexes(22). Interestingly chemical 
structure of CCK is similar to gastrin and both hormones have similar characteristics. 
Secretin and CCK complement each other by using two different intracellular 
pathways: Secretin the adenylate cyclase, CCK the phospholipase C system. As 
consequence, after being stimulated by a meal, secretin and CCK potentiate their 
effect on acinar enzyme output(23;24).  
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CCK Stimulates Pancreatic Enzyme Secretion by Both Neural and Hormonal Pathways. From: 
Pandol, Stephen J. (2015). Normal Pancreatic Function.; Open source 
Historically, three phases of pancreatic secretion are important. The cephalic phase 
induced by olfactory, gustatory, optical and commemoration factors leading to 
efferent vagal stimulation. The gastric phase has its origin in gastric distention 
leading to a gastro pancreatic reflex. The intestinal phase is most important. Gastric 
Chyme in the small bowel provokes nerve and hormonal response. Maximal output of 
stimulated pancreas juice is 20-50% of total output in the cephalic phase, 10% in the 
gastric phase and 50-100% in the intestinal phase(25).  Other authors describe a 
fourth phase, the absorbed nutrient phase(14). Bicarbonate output is strongly 
associated with entering of gastric chyme in the duodenum, S-cells there may give 
maximal secretin output if the pH is <four.(26;27) 
A portal system links the islet cells together with the acinar cells. Via this exocrine – 
endocrine axes insulin interplays with centro-acinar and acinar cells. Increase of 
bicarbonate, water and electrolytes and amylase output is the consequence(28;29).  
Enzymes and zymogens in pancreatic juice ferment the chyme to molecules, which 
are able to cross the intestinal brush border into the portal venous system.  
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Enzymes 
Already the cephalic phase stimulates enzyme output via vagal activity(30). Meals 
stimulate secretion of enzymes, followed by synthesis of enzymes in  fasting 
periods(11). Acini in the pancreas are in distance to the location of digestive activity 
making secretion via the pancreatic ducts into the duodenum necessary. To prohibit 
pancreatic auto digestion, the acini deliver not enzymes, but inactive precursors. Only 
with sufficient bicarbonate production, pH optimum of pancreatic enzymes can be 
reached (trypsin 7.5-8.5, chymotrypsin 7.8-8.0, elastase 8.5, lipase 7.0-8,0, amylase 
7.0). The interplay of enzymes and substrate and velocity of cleavage is equivalent to 
the term enzyme kinetics. It can be described as mathematic equation(31). Enzyme 
output may be selectively, as shown in the fourth phase of pancreatic stimulation, the 
nutritional phase. After duodenal infusion with amino acids, output of Proteases is 
increased, but not output of Amylase and Lipase(32). Loss of enzyme activity is 
different from enzyme to enzyme. From duodenum to ileum activity of  lipase is 
reduced 99 %,  of amylase 26% and  of trypsin 78 %  (33). 
An intensive discussion about the destiny of enzymes is ongoing. Three mechanisms 
are important: Activation and inactivation of enzymes, cleavage of enzymes  and 
recycling via the enteropancreatic circulation(34).  
Proteases (zymogens) 
80 % of the mass in pancreatic enzymes are proteases, but proteins stand only for 10 
% of calorie intake in western diet(15). Peptides in the stomach have a pH optimum 
of 1.8 to 3.5 and are an important precondition for further cleavage by pancreatic 
proteases in the small intestine. Peptidases from the small intestine as 
aminopeptidases, 2 carboxypeptidases, 2 endopeptidases and γ -glutamic trans 






In 1876, Kühne described the enzyme and its maximum action in alkaline milieu. He 
recognized that it  cleaves proteins in chyme(36). Today we know that it 
preferentially hydrolyses peptides at the site of basic amino acids (lysine and 
arginine). Trypsin represents 19% of protein in pancreatic juice(15). 
The precursor Trypsinogen produced in the acinar cells occur in three isoforms: 
cationic (PRSS1), anionic (PRSS2) meso trypsinogen (PRSS3)(37).  Enteropeptidase 
from the small bowel mucosa converts trypsinogen to trypsin. Once activated, a 
process of auto activation begins.  
 
From: Pandol, Stephen J. (2015). Normal Pancreatic Function. Pancreapedia: Exocrine Pancreas 
Knowledge Base; Open source 
Trypsin also activates other pancreatic zymogens, like chymotrypsinogen, 
proelastase, procarboxypeptidase and prolipase once they are secreted in the 
duodenum(38).  Pepsin provokes degradation of trypsin. Pancreatic secretory trypsin 
inhibitor is located in the same zymogen granule as trypsinogen. A small amount of 
activation of trypsinogen to trypsin in acinar cells makes the presence of trypsin 
inhibitor in acinar cells mandatory. In genetic failures (mutations of PRSS1, SPINK) 
impaired inhibition process leads to pancreatitis. The same process is coming up if 
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there is an overstimulation or overproduction of trypsinogen compared to trypsin 
inhibitor(39). Additionally, calcium overload in acinar cells triggers trypsinogen 
activation(39) . In CFTR mutations lack of flushing water in pancreatic ducts delays 
trypsinogen output and activated trypsin remains in the ductal part of the 
pancreas(40). Trypsin and trypsin inhibitor seem to influence pancreatic secretion by 
a negative feedback mechanism: trypsin in duodenum is limiting pancreatic secretion, 
trypsin inhibitor stimulates output of pancreatic juice (41). Remarkably, these basic 
processes, forming the underlying theoretical pathological mechanisms in pancreatic 
physiology are mostly evaluated in rats, and may not be equal in humans.  
Chymotrypsin  
Preferential cleavage: hydrolyses peptides involving aromatic amino acids 
(phenylalanine, tyrosine, tryptophan)(15). It is about 9% of protein in pancreatic 
juice(42).  
The synthesis of chymotrypsinogen takes place in acinar pancreatic cells and trypsin 
in duodenal chyme activates it. Beside the proteolytic activity it is also an esterase 
and amidase(42). Like trypsin and elastase, it hydrolyses polypeptide chains. Beside 
its proteolytic activity, it is involved in control of blood pressure and blood clotting. It 
is one of the most studied enzymes because it’s stable and can be easily obtained(43). 
Four isoforms exist: B1 (CTRB1), chymotrypsinogen B2 (CTRB2), 
chymotrypsinogen C (CTRC), and chymotrypsin-like enzyme-1 precursor 
(CTRL1)(37). 
Elastase  
This enzyme hydrolysis proteins, including elastin. Elastase splits the protein 
backbone at bonds at uncharged small amino acids (such as alanine, glycine, and 
serine)(15). 
In 1950 it was shown that the proteolytic activity of  trypsin and chymotrypsin was 
not as effective in cleavage of elastic fibres  as a factor X in pancreatic juice, called 
elastase(44). This was the discovery of the third serine protease in pancreatic juice. In 
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zymogen granules of the acinar cells, it is stored as a precursor called proelastase. 
Trypsin activates it in the duodenum. The isoforms proelastase 2A (ELA2A), 
proelastase 3A (ELA3A) and proelastase 3B (ELA3B), are identified as active 
proteases once activated by trypsin in duodenal juice (45).  
Carbopeptidase1  
Carboxypeptidases exist as isoforms and are as the other proteases stored in the 
acinar cells as precursors, procarboxypeptidase A1 (CPA1), procarboxypeptidase A2 
(CPA2) and procarboxypeptidase B1 (CPB)(46).  
Carboxypeptidase-A attacks the last amino acid of a target peptide chain when it is 
aromatic, neutral, or acidic, while carboxypeptidase-B attacks basic amino acids(15). 
Lipases  
As early as in 1849 Claude Bernard described the hydrolysis of triacylglycerol in 
human duodenal juice(47) Pancreatic lipase cleaves dietary fat as follows: 
triacylglycerol + H(2)O <=> diacylglycerol + a carboxylate.  
Long chain triglycerides stand for 92-96% of fat content in western diet which is 
at least 100g total fat / day(48). Dietary fat stands for 42% of calorie intake in the 
western world(49).Typical American food calorie content is divided in 35% fat, 
15% proteins and 50% sugar(50). Worldwide food intake differs considerably(51). 
The pancreatic enzyme acts only on an ester-water interface; the outer ester links 
are preferentially hydrolysed(52;53). Bile salts for emulsification and colipase for 
linking the active enzyme to the water interface are needed(52). Additionally 
colipase compensates for the inhibitory potential of bile salts, phospholipids, 
cholesterol esters, dietary proteins and dietary carbohydrates(54). 
In moderate to severe exocrine pancreatic insufficiency, absorption of up to 70% 
of triglycerides in the small bowels is possible. A possible explanation is the 
existence of human gastric lipase. Human gastric lipase does not only cleave 
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triglycerides in the stomach, its activation in the duodenum by bile salts plays an 
important role(55). 
Carboxyl ester lipase CEL 
This enzyme hydrolyses triglycerides, cholesterol esters, phospholipids, 
lysophospholipids, ceramides, vitamin esters and galactolipids(56). 4% of protein 
mass in pancreatic juice is CEL(57). Newer studies elucidated the importance of this 
enzyme (58-60). 
Amylase  
The enzyme works by Endo hydrolysis of (1->4)-alpha-D-glucoside linkages in 
polysaccharides containing three or more (1->4)-alpha-linked D-glucose units. 
Pancreatic α-amylase catalyses breakup of starch into malto-oligosaccharides in 
the gut. Cleavage of them by gut wall α-glucosidases split oligosaccharides to 
glucose(61). About 40 to 50% of Western diet consists of Carbohydrates(62). 5-6% 
of pancreatic juice consists of this enzyme. Unlike proteases, it is not stored as an 
inactive precursor in acinar cells and is the only glycogen cleaving enzyme in 
pancreatic juice(63). Even without pancreatic amylase about 80 % of complex 
carbohydrates can be absorbed(64). Probably other amylases can compensate this 
deficiency. Salivary Amylase can partly compensate(65). 
Chronic pancreatitis 
Today, widespread guidelines for the diagnosis and management of CP exist. They all 
reflect historical development of understanding physiology, pathophysiology and 
epidemiology, with consecutive approach to diagnosis and treatment (66-68). 
However, a new way of thinking with a mechanistic definition of a multifactorial 
syndrome may change our understanding and clinical approach to CP (69). 
CP affects the pancreas by different mechanisms. It is not one entity or clearly 
defined disease but rather a conglomerate of pathophysiological processes leading to 
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various symptoms as abdominal pain and discomfort, nausea, loose stools, 
malnutrition and weight loss (70;71). Not all symptoms occur in every patient. Often 
the course begins with acute pancreatitis leading to recurrent acute pancreatitis and at 
the end CP with loss of pancreatic function (70-73). Not all patients are symptomatic 
and diagnoses appears accidentally by hyperamylasaemia or hyperlipasemia, severe 
maldigestion in end-stage CP or even in post mortem examination (74-76). 
Frequently, not only one, but also several risk factors linked together will cause CP 
(77). 
Morphologic changes are the consequence of chronic inflammation(78). 
Calcifications, duct irregularities, pseudocysts, atrophy are the main findings(79). 
Subtle changes have been described by advanced imaging methods(80). 
 
From: Aghani, Elham.(2015). Introduction to Pancreatic Disease: Chronic pancreatitis. 
Pancreapedia: Exocrine Pancreas Knowledge Base; Open source. 
Chronic inflammation involves exocrine pancreas with progressive loss of pancreatic 
function by damaging ductal and acinar cells (81). Destruction of stellate cells causes 
fibrosis (82;83). In end stage of CP, Langerhans islets are also involved, with 
impairment or loss of endocrine function and diabetes type 3c occurs (84). At any 
stages of CP, pancreas cancer can occur (85;86). 
Alcohol consumption is the most frequent cause of CP; however, the 
pathophysiological mechanism is still not clear. Not all patients with high intake of 
alcohol get CP, but also patients’ consuming relatively low quantities of alcohol are 
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in risk for development of CP. Most studies based on epidemiology classify alcohol 
as risk factor rather than a pathophysiological entity(87). Possibly alcohol and its 
metabolic products sensitize the pancreas for necroinflammatory processes (88). 
Other co-factors may lead to the deleterious process called acute or CP. Newer 
studies postulate minor CFTR activity, and direct toxic effects to acinar and stellate 
cells, partly due to augmented mucosal permeability in the small bowels(89). 
Smoking is also an important risk factor often linked to alcohol; epidemiological 
studies in the last years have confirmed its importance (90-92).  Nicotine and nicotine 
derived nitrosamine ketone trigger acinar cells to zymogen output involving CCK and 
preganglionic nicotine receptors(93).  Nitric oxide may be the cause of microvascular 
changes, and nicotine may impair CFTR function (94). 
Gallstones can block the main pancreatic duct if they are located proximally the 
papilla of Vater(95). In unrecognized coincidental other risk factors, they can lead to 
CP. Prompt endoscopic or surgical radical treatment in acute gallstone related 
pancreatitis is the key to prevent mortality in acute pancreatitis, recurrent acute 
pancreatitis, and consequently chronic pancreatitis(96). 
Anatomical variants as annular pancreas or pancreas divisum can lead to pancreatitis. 
Mostly they are asymptomatic (97). Only in case of obstruction, these anatomic 
variants trigger inflammation processes (98;99). Coincidental efferent obstruction and 
genetic mutations of PRSS1, SPINK or CTRC can induce activation of zymogens 
(97). 
Genetic mutations have drawn attention in the last years (100;101). They are the key 
to intrapancreatic activation of serine proteases especially trypsin which activates 
most other pancreatic enzymes(102). If once activated, auto digestion process is 
ongoing. Referral of young patients with idiopathic pancreatitis to genetic assessment 
should be mandatory. Consequent advice to avoid known risk factors may prevent 
repeated attacks of pancreatitis with impaired exocrine function over time and  risk 
for development of pancreatic cancer could be minimized in a patient group with 
augmented frequency of pancreatic malignancy(103). Combination of diabetes with 
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exocrine pancreatic insufficiency is suspicious for CEL-MODY if several members 
of a family over generations are involved (60). Mutations of CFTR gene can lead to 
cystic fibrosis with pancreatic phenotype. Sticky, mucinous pancreas juice reaches 
duodenum marginally, auto digestion with mild progressive pancreatitis, loss of 
function and fibroses in young age are the consequences (104;105).   
In tropical pancreatitis, rapid calcifying pancreatitis with intraductal stones and 
diabetes, beginning in young age are the main characteristics. In traditional theories, 
malnutrition and overconsume of cassava are the causal factors.  Recently, SPINK1 
mutations were found in up to 64% in patients with tropical pancreatitis, 50% 
homozygote and 14 % heterozygote(106). CFTR mutations alone or in combination 
may also occur. Thus, some authors point out  that malnutrition is not cause but a 
consequence of  tropical CP (107). 
Hypertriglyceridemia alone or in combination with other risk factors can trigger 
pancreatitis. Hypertriglyceridemia often reflects the fact that pancreatitis is a 
multifactorial disease with different risk factors at the same time. Alcohol and biliary 
obstruction are the most important examples(108). As single factor, triglycerides have 
to be as high as over 20 mmol/L to induce pancreatitis(109). Still, 
hypertriglyceridemia type IV with high triglyceride levels causes up to 20% 
pancreatitis in some materials. Chylomicrons my cause microvascular ischemia. 
Combination of long standing hypertriglyceridemia with mutations are not rare, 
lipoprotein lipase deficiency is an example(110).  
Hypercalcemia often due to hyperparathyroidism activates zymogens intrapancreatic, 
inducing an inflammatory cascade(111). Calcium plays an important role in 
pancreatitis, as calcifications are a diagnostic hallmark of CP. In principle, 
calcifications are the result of saponification with fatty acids and precipitate as 
salts(112). Older studies describe unbalance between Calcium and bicarbonate 
leading to precipitation of Calcium carbonate stones(113). A human stone protein 
plays also a role in the pathogenesis of pancreatic stones(114).     
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Autoimmune pancreatitis is an own entity first described by Yoshida in 1995(115). 
Emerging knowledge has classified two types; an IgG4 mediated autoimmune disease 
with obstructive jaundice and the idiopathic duct centric pancreatitis mimicking AIP, 
partly associated with inflammatory bowel disease(116). Confounding AIP with 
pancreatic cancer is a serious obstacle. Inadequate action with irreversible mutilations 
as a Whipple`s operation instead of immunosuppressive treatment are not rare. 
Pain in chronic pancreatitis 
Severe chronic abdominal pain is a serious and the dominant complaint in CP 
patients, regardless to aetiology. Insufficient nutrition, work disability, drug addiction 
and lack of participation in social life is the consequence (117). 
 
With permission from Olesen, Søren Schou. Tieftrunk, Elke. Ceyhan, Güralp O. Drewes, Asbjørn 
Mohr. (2015). Pathogenesis and Treatment of Pain in Chronic pancreatitis. Pancreapedia 
The decades-long assumption that the causes of pain in CP are efferent factors like 
ductal compression or obstruction is fading. Chronic pain in pancreatitis is more 
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complex than assumed before. Neuropathic pain seems to play a key role in CP. 
Chronic inflammation and fibrosis cause hypertrophy and increased density of 
pancreatic nerves (118). Growing evidence explains the pathophysiological part of 
chronic pain by sensitization of afferent nociceptive fibres. Hyperalgesia related to 
food intake is seen as an inadequate response of the spinal cord and pain brain 
centres. Somatic and visceral impulses from other organs, peripheral muscles or skin 
may be misinterpreted as pain signals due to excitation of afferent nerves in the spinal 
cord altering the sensory processing in the brain. In other words, spontaneous axon 
firing leads to impulsive firing of the dorsal horns neurons. The result is stimulus 
independent pain i.e. firing of the c-fibre even though it is not stimulated. Over time, 
the spinal cord becomes independent from signals with origin in the pancreas leading 
to cortical reorganization.  This may explain chronic opioid dependent pain after total 
pancreatectomy(119-124).  
Despite better understanding of pathophysiology of pain, medical therapy remains a 
unsolved challenge(125).  
Classification of chronic pancreatitis 
Most classification systems are based on etiologic, morphologic, functional and 
clinical information(126). 
The Marseille classification from 1963 consists of clinical information and histology. 
It differentiates between four types of pancreatitis: Acute pancreatitis, acute relapsing 
pancreatitis, chronic relapsing pancreatitis and asymptomatic CP. Acute pancreatitis 
was seen as a severe disease which could been cured meanwhile CP was seen as a 
progressive process which could not be stopped(127;128).  
In 1983, the Cambridge-classification pointed out morphological features as imaging 
studies gave crucial new insights. It is an ERCP based duct focused grading, which 
was later adapted by CT and MR(CP) with the advantage that also organ size and 
parenchymal features could be included(129). 
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Interestingly, in 1983, Lankisch et al. recognized the importance of pancreatic 
exocrine insufficiency and proposed a three step loss of pancreatic function with 
direct pancreas function testing and faecal fat output: pancreatic enzymes in duodenal 
juice were indicative for all grades of exocrine pancreatic insufficiency (EPI); 
meanwhile bicarbonate output  was impaired in moderate and severe, and faecal fat 
only in severe PEI(130).  
The TIGAR-O classification (2001) is describing main etiologic factors of CP: Toxic- 
metabolic, idiopathic, genetic, autoimmune, recurrent acute pancreatitis and 
obstructive causes. This classification is  of importance because of it emphasizes that 
CP is a multifactorial disease with sometimes more than one triggering factor(131).  
In 1994, Layer described a clinical scoring system to diagnose CP, later called 
MAYO diagnostic scoring system for CP. It also has three parts: a) Morphology:  
pancreatic calcifications, histology, pancreatic duct abnormalities after the Cambridge 
classification; b) Exocrine pancreatic function:  steatorrhea or lipase output, diabetes 
(type 3c); c) classical clinic appearance: upper abdominal pain or weight loss over 10 
kg in 12 months (74;132).  The scoring system of the Japanese pancreas society is 
similar to this score and separates definite from probable CP(133). 
The M-ANNHEIM classification system published in 2007 is a multimodal synopsis 
of former classification systems(134). 
Module 1 describes etiological factors analogue to the TIGAR-O classification. It 
emphasises the importance of multiple risk factors (M Pancreatitis). Then the most 
frequent causes of CP in Europe are listed: Alcohol (A) graded in three quantity 
categories and smoking (N) expressed by pack years. Nutritional (N), hereditary (H), 
Efferent duct (E), immunological (I), and miscellaneous factors (M): 
 
The M-ANNHEIM multiple risk factor classification of chronic pancreatitis 
M Pancreatitis with Multiple risk factors 
A   Alcohol consumption 
Excessive consumption (>80 g/day) 
Increased consumption (20–80 g/day) 
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Moderate consumption (<20 g/day) 
N   Nicotine consumption 
(In cigarette smokers: description of nicotine consumption by pack-
years) 
N   Nutritional factors 
Nutrition (e.g., high caloric proportion of fat and protein) 
Hyperlipidaemia 
H   Hereditary factors 
Hereditary pancreatitis (defined according to Whitcomb(135)) 
Familial pancreatitis (defined according to Whitcomb(135)) 
Early-onset idiopathic pancreatitis 
Late-onset idiopathic pancreatitis 
Tropical pancreatitis 
(possible mutations in the PRSS1, CFTR, or SPINK1 genes) 
E   Efferent duct factors 
Pancreas divisum 
Annular pancreas and other congenital abnormalities of the pancreas 
Pancreatic duct obstruction (e.g., tumors) 
Posttraumatic pancreatic duct scars 
Sphincter of Oddi dysfunction 
I   Immunological Factors 
Autoimmune pancreatitis 
Sjögren syndrome-associated chronic pancreatitis 
Inflammatory bowel disease-associated chronic pancreatitis 
Chronic pancreatitis with autoimmune diseases 
(e.g., primary sclerosing cholangitis, primary biliary cirrhosis) 
M   Miscellaneous and rare metabolic factors 
Hypercalcemia and hyperparathyroidism 
Chronic renal failure 
Drugs 
Toxins 
Adopted from A. Schneider et al.: M-ANNHEIM classification 
 
Another module describes clinical staging in four steps, with subdivision in up to 
three categories: zero (asymptomatic), I symptomatic, without EPI, II symptomatic 
and partial EPI, III symptomatic with pain and complete EPI, IV symptomatic 
without pain, but total EPI: 
M-ANNHEIM clinical staging of chronic pancreatitis 
Asymptomatic chronic pancreatitis 
0 Stage of subclinical chronic pancreatitis 
a Period without symptoms (determination by chance, e.g., autopsy) 
b Acute pancreatitis -single episode (possible onset of chronic pancreatitis) 
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c Acute pancreatitis with severe complications 
 
Symptomatic chronic pancreatitis 
I Stage without pancreatic insufficiency 
a (Recurrent) acute pancreatitis (no pain between episodes of acute pancreatitis) * 
b Recurrent or chronic abdominal pain (including pain between episodes of acute 
pancreatitis) 
c I a/b with severe complications 
II Stage of partial pancreatic insufficiency 
a Isolated exocrine (or endocrine) pancreatic insufficiency (without pain) 
b Isolated exocrine (or endocrine) pancreatic insufficiency (with pain) 
c II a/b with severe complications 
III Stage of painful complete pancreatic insufficiency 
a Exocrine and endocrine insufficiency (with pain, e.g., requiring pain medication) 
b III a with severe complications 
IV Stage of secondary painless disease (burnout) 
a Exocrine and endocrine insufficiency without pain and without severe complications 
b Exocrine and endocrine insufficiency without pain and with severe complications 
Adopted from A. Schneider et al.: M-ANNHEIM classification 
Module 3 defines the diagnostic criteria of CP. Classical clinical features are 
required. According to the Zurich workshop, it classifies into definite and probable 
CP(136). The M-ANNHEIM classification system adds a borderline category. It 
includes patients with classical symptoms but no morphological and functional 
features. Additionally, it emphasises the importance of alcohol consumption. 
Classical histology, calcifications, persistent EPI or moderate marked duct changes 
after the Cambridge classification specify definite CP. Mild duct alterations, 
pseudocysts, endocrine insufficiency, or pathological EPI test define probable CP.  
M-ANNHEIM diagnostic criteria of chronic pancreatitis 
The diagnosis of chronic pancreatitis requires a typical clinical history of chronic pancreatitis 
(such as recurrent pancreatitis or abdominal pain, except for primary painless pancreatitis).  
Definite chronic pancreatitis is established by one or more of the following additional 
criteria: 
1. Pancreatic calcifications 
2. Moderate or marked ductal lesions (according to the Cambridge classification) 
3. Marked and persistent exocrine insufficiency defined as pancreatic steatorrhea markedly 
reduced by enzyme supplementation 
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4. Typical histology of an adequate histological specimen 
Probable chronic pancreatitis is established by one or more of the following additional 
criteria: 
1. Mild ductal alterations (according to the Cambridge classification) 
2. Recurrent or persistent pseudocysts 
3. Pathological test of pancreatic exocrine function (such as faecal elastase-1 test, secretin 
test, secretin-pancreozymin test) 
4. Endocrine insufficiency (i.e., abnormal glucose tolerance test) 
Borderline chronic pancreatitis is already established and is defined by a typical clinical 
history of the disease but without any of the additional criteria required for definite or 
probable CP. This form is also established as a first episode of acute pancreatitis with or 
without a family history of pancreatic disease (i.e., other family members with acute 
pancreatitis or pancreatic cancer) or the presence of M-ANNHEIM risk factors. 
 
Pancreatitis associated with alcohol consumption requires in addition to the above-
mentioned criteria for definite, probable, or borderline chronic pancreatitis one of the 
following features: 
1. History of excessive alcohol intake (>80 g/day for some years in men, smaller amounts in 
women) or 
2. History of increased alcohol intake (20–80 g/day for some years) or 
3. History of moderate alcohol intake (<20 g/day for some years) 
Adopted from A. Schneider et al.: M-ANNHEIM classification 
The imaging module complies the Cambridge classification and integrates 
transabdominal and endoscopic ultrasound, CT, MR and MRCP: 
M-ANNHEIM pancreatic imaging criteria for US, CT, MRI/MRCP, and EUS based on 
imaging features as defined by the Cambridge classification 
 




Quality study depicting 





One abnormal feature  
Four or fewer abnormal 
features (no differentiation 
between equivocal and 
mild) 
Mild changes Two or more abnormal 
features, but normal main 
pancreatic duct 
Moderate changes Two or more abnormal 
features, including minor 
main pancreatic duct 
abnormalities (either 
enlargement between 2 and 
4 mm or increased 





Five or more abnormal 
features (no differentiation 
between moderate and 
marked) 
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Marked changes As above with one or more 
of the required features of 
marked changes (4 points)  
Adopted from A. Schneider et al.: M-ANNHEIM classification 
   
 
Another module deals with grading of clinical features as pain, pain control, surgical 
interventions, exocrine and endocrine insufficiency, morphological status on 
pancreatic imaging and severity of organ complications: 
M-ANNHEIM scoring system for the grading of clinical features of chronic pancreatitis 
Clinical features  Points 
Patient report of pain 
No pain without therapy 
Recurrent acute pancreatitis 
 
 










Patient reports requiring no pain medication  
Recurrent acute pancreatitis (patient reports 
freedom from pain between attacks of acute 
pancreatitis) 
No pain with therapy (patient reports freedom 
from pain with pain medication or endoscopic 
intervention) 
Intermittent pain (patient reports intermittent 
pain-free episodes, either with or without 
therapy; possibly additional attacks of acute 
pancreatitis) 
Continuous pain (patient reports absence of 
pain-free episodes, either with or without 















No medication  
Use of no opioid drugs or use of mild opioids (WHO step 1 or 2)  










Absence of exocrine insufficiency 
Presence of mild, moderate, or unproven exocrine insufficiency not requiring 
enzyme supplementation (including patient reports of intermittent diarrhoea) 
Presence of proven exocrine insufficiency (according to exocrine function tests) 
or presence of marked exocrine insufficiency defined as steatorrhea (>7 g fat/24 








Absence of diabetes mellitus  



















Severe organ complications (not included in the Cambridge classification) 
Absence of complications 
Presence of possibly reversible complications 





Adopted from A. Schneider et al.: M-ANNHEIM classification 
 
The sum of points of these modules create a severity index in five categories. 
M-ANNHEIM severity index of chronic pancreatitis 
 
Severity index   Severity level   Point range 
M-ANNHEIM A   Minor    0-5 points 
M-ANNHEIM B   Increased    6-10 points 
M-ANNHEIM C   Advanced    11-15 points 
M-ANNHEIM D  Marked    16-20 points 
M-ANNHEIM E   Exacerbated   >20 points 
Adopted from A. Schneider et al.: M-ANNHEIM classification 
 
Imaging in chronic pancreatitis 
Traditionally imaging describes morphological changes, but as early as in the 
seventies of the last century ultrasound of the pancreas after secretin stimulation 
crossed the border to functional imaging.  
Until upcoming alternative methods, x-ray without intraluminal contrast agents or 
invasive techniques gave only vague information(137). Only calcifications in CP 
gave substantial information.  
Development of B-mode sonography paved the way for transabdominal 
ultrasonography. It showed its potential in pancreas imaging early in the seventies of 
the last century(138). Compared to endoscopic retrograde pancreaticography 
ultrasonography was equal in ductal pathology, additionally it could visualize 
parenchymal findings and was considerably safer and easy to repeat(139). In the last 
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decades, substantial technical development in ultrasonography enhanced the 
ultrasound imaging quality; in given conditions even above other imaging 
methods(140). Furthermore, ultrasonography used for estimation of the pancreatic 
exocrine function after secretin stimulation enriches clinical routine by adding a 
functional parameter to the morphological features (141;142).  Specificity and 
sensitivity of the method is excellent under good ultrasound conditions(143). 
Transabdominal ultrasound is a non-invasive, harmless, widely available, inexpensive 
diagnostic modality. In our opinion, it should be the first- line method for patients 
submitted for both new diagnosis and follow-up of diseases of the pancreas. 
  
Head of pancreas with processus uncinatus scanned with a 15 MHZ transducer. Details shown with 
high resolution. MR: Musculus rectus abdominis; RLL: Right liver lobe; LLL: Left liver lobe; Cap: 
Caput pancreatis; Cor: Corpus pancreatis; Pu: Processus uncinatus; A. mes: Arteria mesenterica 
superior; Vl: Vena lienalis; Agd: Arteria gastroduodenale 
From Erchinger, Transabdominal ultrasonography of the pancreas: basic and new aspects 
 
In 1972 and in 1975, after the invention of the side view duodenoscope, Cotton and 
Koch published their work about ERCP, a method, revolutionizing pancreas duct 
diagnostics and therapy (144;145). With the Cambridge classification, it classified 
morphologically CP as early as in 1973(129). Because of its invasive nature, 
complication rate and operator dependent success, non-invasive techniques, mainly 
MRCP, but also s-MRCP, CT and EUS have, with modifications, replaced diagnostic 
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ERCP (146-148). Today, the significance of ERCP is based on its therapeutic 
potential(149). 
CT of the pancreas was established in the 70ths of the last century(150;151). It was 
cost intensive and artefacts made it comparable to transabdominal ultrasound(152). 
Recent technical development, including the introduction of contrast agents, thus 
obtaining an excellent imaging quality in the majority of the subjects, operator 
independence and availability  have made CT one of the most used imaging 
methods(153). Detection of calcifications strengthen this method in CP 
diagnosis(154). However, micro calcifications can mislead to the diagnosis of CP as 
they can represent arteriosclerosis in intrapancreatic vessels(155). Visualization of 
pancreatic ducts is not optimal, but CT pancreas is in this sentence also adapted into 
the Cambridge classification(146).  
From the beginning of MRI imaging of the pancreas until today, continuous work 
with elimination of artefacts and development of contrast agents have made it to an 
extraordinary method(156). It shows small details, can discriminate from 
parenchymal and ductal malignancy, and can characterize cysts. Only in detection of 
calcifications it is not suitable(157). High cost and thus low availability have limited 
the method in some degree.   
Today, MRCP has in countries with broad access replaced ERCP in diagnoses of 
pancreatic duct abnormalities and can easily be combined with MRI of the 
pancreas(158). It can classify pancreatitis adapted to the Cambridge criteria and can 
find intraductal processes(159). One of the important advantages of MRCP is that 
there is no need for contrast agents. MR contrast agents are not without risk in 
patients with renal insufficiency and can lead to fatal complications as nephrogenic 
systemic sclerosis(160).  
Secretin stimulated MRCP (sMRCP) augments the diagnostic value of MRCP 
additionally. By measuring the volume output of pancreatic juice in the small bowels, 
this method also represents a pancreatic function test (161). However, it cannot 
replace direct pancreas function testing completely as it gives only information about 
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volume of juice in the small bowels, but not its content (bicarbonate concentration, 
enzymes and electrolytes)(162).   
Endoscopic ultrasonography of the pancreas has had an tremendous technological 
development since it was established in the early 80ths of the last century(163).  
Milestones are the invention of radial and linear scanning, implementation of Doppler 
and duplex technique, elastography and use of contrast agents(164). With these tools, 
the method is superior to all other procedures in diagnosing microstructures 
(165;166). In addition, it allows invasive diagnostic (fine-needle-aspiration) and 
therapy (trans- gastral drainage of cysts and necrosectomy in acute pancreatitis).(167-
170). The Rosemont classification has broadened the repertoire of imaging in the 
diagnosis of CP remarkably(171). It gives more information than the Cambridge 
classification as the latter bases only on pathological features of the pancreatic ducts; 
I contrast, the Rosemont classification visualises morphological details unique. 
However, the method is invasive and labour intensive. Especially, operator 
dependence makes inter observer agreement to a challenge(172). 
In conclusion, a variety of methods is used in pancreatic imaging. Availability of 
diagnostic tools and operators experience in different clinical units make it difficult to 
recommend the ideal diagnostic approach. In general, it is wise to begin with an 
imaging method, which is not cost intensive, but gives a good overview. In many 
cases, transabdominal ultrasound can give this information. If not, CT is the next step 
as it is broadly available. If more detailed diagnostic is necessary or if the first 
imaging methods do not solve clinical challenges, MR/MRCP/S-MRCP or EUS are 
appropriate.    
Pancreas function testing 
Diagnosis of EPI is important as its consequences have severe clinical impact and 
may shorten live expectancy (173;174). Consecutive, malabsorption results in 
inadequate uptake of calories, vitamins and micronutrients (175). The most common 
cause is CP(176). Pancreatic cancer, pancreatic surgery, diabetes or inborn errors as 
cystic fibrosis, Schwachman-Diamond syndrome can also lead to EPI (177). Enteral 
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malabsorption in celiac disease, diabetes mellitus, Crohn’s disease, after gastric 
surgery, short bowel syndrome, and Zollinger–Ellison syndrome can mimic EPI i.e. 
secondary EPI (178). 
Direct invasive pancreas function testing 
Direct pancreas function testing is the historical gold standard but its use in clinical 
routine is rare(179). Thus, most of our understanding of pancreatic physiology bases 
on studies performed in the last centuries (180-182).  
The principle of these tests is stimulation of the pancreas by hormones, 
pharmaceuticals or meals. After stimulation of pancreatic secretion and sampling of 
duodenal juice, analyses of bicarbonate, electrolytes and enzymes is possible. The 
tests are invasive, formerly performed with a double lumen tube placed by x-ray 
control. The distal end in the duodenum, the other end in the stomach. These tests are 
time-consuming, work intensive and uncomfortable for the patients, but they are able 
to provide information about volume of duodenal juice in the measured time period 
and concentration of its ingredients(183).  
The test, closest to physiological conditions, seems to be the Lundh test as it  bases on 
a standardized test meal(184).  
Stimulation with secretin and cholecystokinin or its analogue cerulein test both ductal 
and acinar pancreatic function. This may be the reason that all variants of secretin-
CCK tests are been referred as “gold standard” of direct pancreas function testing. 
Compared to the Lundh test pollution of duodenal juice by a test meal is not expected 
(185;186). However, CCK or cerulein, probably due to induction of pancreatitis, can 
have more, partly serious side effects compared to secretin (187;188). CCK induced 
gallbladder contraction can especially in patients with gallstones provoke biliary 
colic(189). Nausea, vomiting and abdominal pain after injection of ceruletide are 
described(190). 
Stimulation with only secretin combined with an upper endoscopy is coming up the 
last years(191). Most articles focus on easy feasibility, performed as a short 
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endoscopic secretin test (192-194). The intention is to shorten the test i.e. make the 
test more “patient friendly” and reduce the whole workload around the test. As it 
stimulates bicarbonate secretion, it – in theory - only measures the ductal function 
and importance for information about acinar function is not yet clear in practice. 
Some authors discuss the potential of diagnosing acinar function with only secretin 
stimulation(195). The role of this short endoscopic test in relation to the classical 
Dreiling tube test and EUS is still under continuous discussion. Especially, when 
performing the short endoscopic secretin test, the cut off of bicarbonate concentration 
in duodenal juice is a topic of interest(196). However, in our mind, there is no doubt 
that the old gold standard test, which requires 2-3 hours sampling time, is not feasible 
any more.  
Bombesin, a peptide from frog skin, stimulates pancreatic acinar function, but also 
detachment of gastrin and acetylcholine. Combination with administration of Secretin 
is possible(197).  
Indirect non-invasive pancreas function tests 
In the NBT-PABA (N-benzoyl-L-tyrosyl-p-amino benzoic acid of bentiromide) test, 
pancreatic chymotrypsin breaks N-PABA down to N benzoyl l-Tyrosine and PABA. 
After intestinal absorption three metabolites are excreted in the urine one of them is 
additionally glucuronated in the liver(198). This test is not in clinical use any more 
and is not valuable in renal insufficiency(199). The serum PABA test may be easier 
to handle and is possibly more accurate(199). 
The Pancreolauryltest bases on metabolism of Fluorescin dilaurate by pancreatic 
specific esterase; the product is absorbed in the small intestine, partly glucuronated an 
excreted in the urine after a sampling period of 10 hours. It is suitable for moderate to 
severe EPI (199;200). In addition, this test is not in clinical use any more. As serum 
test it may be a good alternative in diagnosing mild to moderate EPI and helpful in 
following EPI in patients with CP(201). 
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13C mixed triglyceride breath tests can also diagnose pancreatic insufficiency and are 
in use in the follow-up of patients with diseases leading to progressive EPI, mostly 
CP. Also patient compliance regarding enzyme supplement treatment can be 
checked(202). This is important to rule out other causes of malnutrition and weight 
gain as e.g. cancer. However it is important to take the following pitfalls of the test 
into consideration: physical activity, gastric emptying velocity, lipolytic capacity in 
liver diseases(195). Other disadvantages are long test duration and lack of 
standardization and cost of agents. Additionally, there is need for specialized personal 
and equipment. Therefore, tertiary centres stand for its performance(203).   
Faecal elastase 1 (FE1) is - performed as a spot sample – the most used test to 
diagnose exocrine pancreatic insufficiency in clinical practice. It is a stable molecule 
as there is no cleavage on the way through the bowels. The patients do not have to 
interrupt enzyme substitution, as the pharmaceuticals are the product of porcine 
pancreas and do not interfere with the human elastase test (204). It is of importance to 
advice patients not to collect samples in periods with watery stools. Dilution gives 
false positive results and leads to unnecessary, partly invasive and cost intensive 
diagnostic. Unfortunately, this test can only rule out moderate to severe EPI and is 
not eligible to diagnose early, mild EPI. Sensitivity in detecting mild, moderate and 
severe EPI was described to be superior to the PABA, Pancreolauryl test and faecal 
Chymotrypsin test(205). The most used test in clinical routine is the monoclonal 
FE11 test. Testing all Elastase isomers with polyclonal analyses has not yet been 
accepted, possibly because of additional information is marginal and not of 
importance.  
Chymotrypsin in stool is a good alternative to FE1as it can be used to test patients’ 
compliance to enzyme supplementation(206). However, it is not any more in clinical 
use as FE11 test is dominating clinical routine(207).  
Most authors and textbooks describe faecal fat quantification as the gold standard in 
the diagnoses of steatorrhea, the leading symptom of severe EPI in end stage 
CP(178;208-210). Steatorrhea occurs before protein malabsorption and carbohydrate 
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absorption(211). However, for clinical routine, this test is not in use in most countries 
as compliance to diet containing 100 g fat/day, stool sampling and storing over three 
days is questionable and homogenization of faeces is inconvenient, analyses after the 
protocol of van de Kamer is cumbersome and chemicals are toxic thus requiring 
safety protocols(212). Inconvenience of the test can be reduced. In a small series of 
patients we demonstrated that minimizing of chemicals to the tenth of the original 
protocol is possible and standardized diet and coefficient of fat absorption are not 
necessary(213). Additionally, we were also able to show that healthy controls pass 
the cut off 7g fat/day in the stool up to 9 g fat/day(214). Steatorrhea occurs not only 
in pancreatic malabsorption, but also in infectious diarrhoea, celiac disease or 
inflammatory bowel syndrome as secondary intestinal malabsorption. Some authors 
grade steatorrhea in normal fat output to 7 g/d, steatorrhea of various reasons with fat 
output between 7 and 14 g/d and pancreatic steatorrhea with faecal fat output 
>14g/d(209;215). In conclusion, faecal fat is a cumbersome method in reserve for 
special cases with voluminous stools of unknown origin where other diagnostic tools 
could not lead to diagnoses. 
Acid steatocrit was seen to be more practical than faecal fat quantification, but its use 










2. Aims of this work 
Article I 
Short endoscopic Secretin test 
We investigated if our short variant of the endoscopic pancreas function test, as a part 
of routine upper endoscopy, could improve clinical diagnostics of CP when using 
Layer (Mayo) score. 
We tested the following study hypothesis: our short endoscopic secretin test has 
acceptable diagnostic accuracy for the diagnosis of CP.  
 
Article II 
Automation of bicarbonate measurement 
We aimed to evaluate an automated spectrophotometric method in samples spanning 
the effective range of bicarbonate concentrations in duodenal juice.   
Study hypotheses: 
A) Accuracy of an automated spectrophotometric method is equal to back titration.  
B) Freezing of samples before analyses would not affect its results.  
 
Article 3 
Automation of Amylase measurement in duodenal juice 
We aimed to compare an automated kinetic spectrophotometric method for pancreatic 




 The two methods have good correlation. 
 
Article 4 
Automation of Lipase measurement 
We sought to develop a feasible and time-effective method for measuring lipase 
activity in duodenal juice, using a commercial kit and standardized automated method 
widely available. Secondly, we wanted to evaluate this method by comparing the 
results from a microplate fluorometric, kinetic assay for lipase activity. Additionally, 
we wanted to find chemical supplements, which stabilize Lipase activity over a time 
for sufficient analyses. These reagents should not influence the measurements. 
Study hypotheses:  
A) The two methods have good correlation.  
B) MOPS buffer and Bovine serum albumin give stable results over time. 
 
The combined aim of the project was to integrate direct pancreas function testing in a 
multimodal diagnostic algorithm in the diagnosis of CP.  
This multimodal approach generated many other works, not included in this thesis. 
We evaluated pancreatic enzymes, faecal fat and FE1 (193;213;214;217;218). Our 
research group also compared and validated pancreatic imaging with MRI techniques, 
transabdominal and endoscopic ultrasonography (141;217;219;220). Perfusion 
studies of the pancreas in patients with cystic fibrosis and CP should also be 
mentioned (221;222). Pancreas function testing and imaging studies of patients with 
different kinds of diabetes type III were performed (193;218). Genetic studies 
revealed innovative knowledge (59;223;224). Data from our local CP database were 
integrated in a Nordic Baltic database, to characterize epidemiology, diagnostic, 
treatment and follow-up in the different Nordic countries (225).  
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We limited this thesis to establish direct pancreas function testing as a diagnostic tool 
in clinical routine. By simplifying the method as much as possible, we intended to 
implement it in a routine gastroscopy without exceeding the time schedule in a busy 
endoscopic unit.  Standardized handling and automatizing the process of analysing 



























3. Methodological Aspects 
Patients referred to the outpatient clinic with symptoms suspicious for CP were 
offered to participate. All subjects were included after an informed and signed written 
consent. The studies were approved by the regional ethical committee, REK vest. 
Approval numbers: 2011/590 and 2010/2857-7. The studies were performed 
according to the Helsinki declaration(226). Heathy controls were called attention to 
the project by board notes in our clinic.  
To separate patients with CP from those without, we chose the Layer (Mayo) score, 
with ≥ 4 points as cut off. The following points were summed up: typical histology or 
pancreatic calcifications: 4 points, typical imaging characteristics: 3 points, 
pathological pancreas function test: 2 points, classical abdominal pain lasting at least 
6 month or proven acute pancreatitis in patient’s history: 2 points, Diabetes: 1 
point(74). 
In the original score, FE1 and faecal fat were used for the evaluation of exocrine 
pancreatic function. We used FE1 and bicarbonate concentration in duodenal juice 
from short EST and compared sensitivity, specificity, pos. and neg. predictive values 
for each of the tests. When scoring with bicarbonate concentration was different to 
scoring with FE1, we used the highest sum of points and called it peak score. 




 Short endoscopic pancreas function test; the procedure in detail: 25 minutes after injection of 
secretin (1 CU/kg bodyweight, maximum), upper endoscopy was started. During the first 5 minutes, 
we performed diagnostic gastroduodenoscopy and evacuated all juice from stomach and duodenum. 
Thereafter, the tip of the endoscope was placed distal the papilla of Vater for 15 minutes; duodenal 
juice was sampled in three 5-minute portions. The whole procedure lasted 20 minutes. 
 
Automation of bicarbonate, Amylase and Lipase measurement was performed with 
enzyme-based, spectrophotometric methods. The principle of spectrophotometry: 
White light is bundled up by a lens and send to a monochromator (prism) which splits 
the light in different wavelengths. Only light with a predefined wavelength can pass a 
filter. The filtered light then passes through a sample solution; a part of it is absorbed. 
The difference between “light out” (l1)  and “light in” (lo) can be measured and is 
proportional to enzyme activity(227). 
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Basic structure of spectrophotometers (illustrated by Heesung Shim); in open source 
https://chem.libretexts.org/Core/Physical_and_Theoretical_Chemistry/Kinetics/Reaction_Rates/Expe
rimental_Determination_of_Kinetcs/Spectrophotometry 
The principle of enzyme based bicarbonate, amylase and lipase measurement with an 
autoanalyzer usually used in routine diagnostics is explained as follows: 
In bicarbonate measurement, the enzyme added to the sample solution (duodenal 
juice) is phosphoenolpyruvate carboxylase; finally, NADH is losing a Hydrogen, 
which leads to absorption of filtered light with a predefined wavelength.  
In amylase measurement, α-glukosidase is the enzyme used in chemical reactions 
leading finally to nitrophenol. Its absorption is direct proportional to Amylase 
activity. 
In Lipase measurement, the final product is Methylresorufin; its colour intensity is 
direct proportional to Lipase activity. The chemical reaction needs colipase and 
cholates from the biliary system. 
Calibration of the autoanalyzer is necessary and performed with a commercial 
available Multi-Kit with known bicarbonate concentration or enzyme activity.  
The older standard measurement of bicarbonate concentration is back-titration(228). 
The principle is to measure pH before strong acid HCl is added; after evacuation of 
Carbondioxide by stirring leading to evaporation, a strong chemical base, NaOH, is 
added to titrate back to the pH measured before the procedure. By a formula, the 
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amount of evaporated bicarbonate is calculated. We analysed in parallels and always 
with a solution of known bicarbonate concentration (control).  
The older enzyme-activity semi-automated measurement methods for amylase used 
in this work is finally also a spectrophotometric method. Lipase is measured by a 
fluorometric method. The preparation of the sample solutions is a complicated, 
manual multistep procedure.  It is important to mention that these methods are always 
linked to a standard curve with blanks as baseline; a common approach is to measure 
in Triplets; a ≤ 10% coefficient of variance was obligatory, otherwise the result was 
not used because of its inaccuracy.  
The semi-automated old measurement of amylase-activity is based on an analyses 
procedure used over decades, the Phadebas method(229). Starch with blue dye is 
cleaved exclusively by alpha amylase; its colour intensity is measured over a defined 
time and is proportional to Amylase activity.  
The older lipase measurement needs colipase as additive and a fluorescent, linked to a 
chemical bond with glycerol, which is the central reagent. The increase of 
fluorescence activity is directly proportional to Lipase activity (230;231).  
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4. Main Results 
4.1. Short endoscopic secretin test 
We demonstrated that the short endoscopic Secretin test, implemented in the clinical 
Layer score, showed better sensitivity and specificity than FE1. We could diagnose 
patients with symptoms suspicious for CP more precisely. In cases with inconclusive 
basic diagnostic, the test was helpful to diagnose pancreatic insufficiency early. Thus, 
we strongly believe that this test, performed in a multimodal sense (Layer score) 
could be useful in diagnosing early and mild CP (67;232). Furthermore, we used the 
time between secretin injection and maximal bicarbonate output after 30 minutes to 
perform secretin stimulated ultrasonography of the pancreas and duodenum. That 
gave us instant knowledge of the pancreatic structure i.e. diagnostic imaging of the 
pancreas. Secondary, grade of early dilatation of the pancreatic duct followed by 
liquid filling of the duodenum gave an estimate of the pancreatic secretory function, 
before the endoscopy. Finally, the endoscopy provided us with pancreatic juice and 
the possibility to analyse the content (bicarbonate and enzymes). Low bicarbonate 
level and low enzyme concentration can lead to a proper diagnosis, even when 
clinical symptoms and imaging is inconclusive.   We conclude that EST is rapid and 
easy to perform and incorporation in daily routines to diagnose CP is possible. 
4.2. Bicarbonate in duodenal juice 
We could show that automated measurement of bicarbonate in duodenal juice was 
equal to back titration in the range of interest. Strongest correlation was at the cut off 
(80 mmol/L). With automation, bicarbonate measurement is much easier to perform. 
Freezing in nitrogen and thawing did not influence the results. 
4.3. Amylase in duodenal juice 
Fluorometric, semi-automated analyses showed good correlation to automated 
measurement. Simplification of amylase measurement succeeded. 
4.4. Lipase in duodenal juice 
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We could establish automated measurement of Lipase in duodenal juice and shorten 
time of analyses considerably. Duodenal juice samples diluted in MOPS buffer added 
BSA have excellent stability at room temperature within normal analysis time. 

















5.1. Short endoscopic secretin test 
Direct pancreas function testing is the gold standard in the diagnoses of exocrine 
pancreas insufficiency (179;180;233). The old standard tests with a test meal or direct 
hormonal stimulation with secretin and/or Cholecystokinin base on measurement of 
volume and concentration of different ingredients of pancreatic juice. They are time 
consuming (about 2 hours), cost intensive and inconvenient for the patient 
(179;234;235). The old methods of bicarbonate, enzyme and electrolyte measurement 
require laboratory staff with special competence and specific equipment. All factors 
described above make direct pancreas function testing too troublesome to establish in 
today’s clinical routine. 
Even if the short endoscopic secretin test is concentration and not volume based, it 
gives reliable results and is more precise than FE1, the only pancreas function test 
available for all, from the general practitioner to the high-specialized pancreatologist.  
A generally accepted cut off 80 mmol/l bicarbonate concentration after secretin 
stimulation must be interpreted with caution when using the short endoscopic secretin 
test. Contamination with gastric juice, regurgitation of juice of the small bowels when 
vomiting, different secretion of mucosal glands, delayed or early plateau of 
bicarbonate concentration weaken the cut-off. We could minimize these pitfalls by 
using three aliquots of five minutes between 30 and 45 minutes after secretin 
injection. In the diagnoses of exocrine pancreatic function, it is essential to find 
values below the cut-off. Consecutively we chose the highest measurement result of 
the three aliquots (“peak-bicarbonate”).  
In proven pancreatic malabsorption, there is no indication for the endoscopic secretin 
test. In most cases, a multimodal approach gives enough information using the 
synopsis of clinical, laboratory, imaging parameters and FE1or more rarely faecal fat 
analyses. However, in doubt, the test is of high value, especially in early CP with 
possible exocrine pancreatic insufficiency(232). The test can also differentiate 
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between enteral and pancreatic malabsorption, as FE1is commonly false positive in 
watery diarrhoea and pathological results for faecal fat tell us about fatty 
malabsorption without its cause.  
In addition, by collecting duodenal juice after Secretin Stimulation, analyses of not 
only bicarbonate and enzymes, but also electrolytes, salts and genetic material from 
the pancreatic tissue is possible(224;236). This may open for diagnosis of early EPI, 
selective diagnosis of impaired acinar or ductal cell function and patients in risk for 
fast accelerating pancreatitis with loss of pancreatic function and cancer.  
The main advantage of the test is the ease in performance. One can implement it in a 
routine gastroscopy, abolishing the need for highly specialized operators or 
equipment. Compared to the old tests, the shortness of collection time minimizes 
volatility of bicarbonate and degradation of enzymes in the time from collection of 
duodenal juice to pre-analytical preparation of the samples. Additionally, as shorter 
the length of a procedure, as more easily it can be tolerated by the patient 
However, there are several limitations: 
CP is complex and an easy to use clinical score cannot reflect all the facets of 
aetiology, pathogenesis, and morphological, functional and clinical aspects. 
Furthermore, the definition of CP is under ongoing discussion (69). Especially around 
the cut off 4 points in the CP score after Layer, the diagnostic value remains a 
challenge. 
The only way to overcome the “twilight zones” around the cut off 4 points in the 
Layer (Mayo) score is a structural follow-up of patients in the outpatient clinic and 
repetition of diagnostic procedures. The foundation of the Scandinavian-Baltic 
pancreas database in 2015 as a structured, multimodal tool, gives the possibility to 
harmonize diagnosis, follow-up and therapeutic options over the involved countries. 
A challenge of this proceeding in follow-up is to decide when invasive procedures 
like EST or EUS, a radiological method (CT) or a cost intensive method (MRI) are 
indicated again, as they cannot be repeated too often. Thus - the old clinical “gut 
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instinct” practiced over several millenniums in medical professions remains as the 
only solution with all its disadvantages and inaccuracies. In our clinic, we have 
incorporated transabdominal ultrasound in the structured follow-up of CP patients or 
patients with symptoms, strongly suspicious for CP, but negative score. In good 
conditions for performance of ultrasonography, this non-invasive, cost-effective and 
repeatable method can evaluate pancreatic morphology partly after the Rosemont 
criteria and help to overcome the obstacles described above to a certain degree (217). 
The cut off 80 mmol/L bicarbonate concentration when performing the endoscopic 
secretin test is not absolute. This may give false results when practicing the clinical 
Layer score. A smart approach to avoid this pitfall may be adaption of the result to 
clinical indication. Our calculations showed a range of bicarbonate concentration 
between 60 and 90 mmol/L to be an intermediate zone. Stevens T. et al. discussed the 
same phenomenon and calculated the best sensitivity and specificity to be at 
bicarbonate concentration of 78 mmol/L(237). Kothari et al.  highlight the same topic 
with a poorer concordance of secretin-stimulated endoscopy, EUS and the old 
Dreiling tube test(238). Even if the design of the latter study was suboptimal (e.g. 
only one sample for bicarbonate analyses, consecutively no use of peak bicarbonate), 
the importance of using a multimodal score is emphasized.  
The number of patients and controls is low; thus, our results should be interpreted 
with caution and optimally confirmed by other study groups.  However, although the 
sample size was relatively small in each individual study, the result was significant. 
Furthermore, our results do not deviate from others’ results in different patient 
groups, confirming the usefulness of the short endoscopic test.  
 We also measured the volumes aspirated from EST. Mean volume was 2.6 mL with 
a range from 0 to 6 ml (not published). Our experience after performance of more 
than 350 EST indicates that volume after Secretin stimulated transabdominal 
ultrasound or MRI may agree with bicarbonate, enzyme concentration and FE1. In 
our group, there is ongoing work to correlate volume of collected duodenal juice to 
volume estimation in ultrasound and bicarbonate or enzyme concentration. 
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5.2. Bicarbonate in duodenal juice 
Bicarbonate in duodenal juice reflects the ductal function of the exocrine pancreas. 
CP causes damage of ductal cells and their membrane, leading to impaired function 
of the cystic fibrosis transmembrane conductance regulator which minimizes the 
output of bicarbonate, water and electrolytes. A wide professional milieu accepts 
bicarbonate concentration in duodenal juice after secretin stimulation as a reliable 
parameter for pancreatic function (191;239). Back titration as the gold standard for 
bicarbonate measurement in duodenal remains juice still remains(234).  
However, immediate analyses are of importance, as we know after the Henderson–
Hasselbalch equation, bicarbonate acts as buffer and can also change to H2O and 
CO2. The latter is highly volatile and thus generates false positive results. Prompt 
analyses by automated measurement could overcome this problem. Handling of this 
technique is superior to back titration, which needs special equipment and specialized 
laboratory staff. Furthermore, the samples can be stored (snap freezing) for later 
analyses, without influencing the results.  
Weakness of automated measuring is, compared to back titration, lower accuracy in 
very high and very low bicarbonate concentration. As an enzyme based method, it is 
dependent on the pH optimum of the enzymes in use. In bicarbonate analysis, the 
automated measurement is most precise in the range of interest between 60 and 90 
mmol/L, including the cut-off 80 mmol/L. Thus – inaccuracy in extreme values is in 
clinical practice of minor importance.   
5.3. Amylase in duodenal juice  
Pancreas amylase activity can be compensated by other amylases. Its deficiency is 
thereby less important in a clinical setting. However, in direct pancreas function 
testing, it may give purer information about exocrine pancreatic insufficiency as it is 
not a proenzyme before it is an active enzyme in the duodenum. Additionally, it is 
stable. Thus, measuring decrease in activity of a pure enzyme without the existence 
of a preliminary state is possibly more precise than the Lipase enzyme with its short 
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activity period or the mixture of proteases and their zymogens. Previously used, 
older, manual multistep methods with boiling are difficult to repeat accurately, time-
consuming and work intensive. Rapid automated measurement overcomes these 
obstacles.  
5.4. Lipase in duodenal juice 
An ongoing intense discussion considers pancreatic lipase as a marker in the 
diagnoses for early exocrine pancreatic insufficiency (240). We chose therefore to 
include pancreatic lipase in our diagnostic repertoire. It is common knowledge that 
lipase activity decreases fast without auxiliary supplies. Consecutively the nihilists in 
direct pancreas function testing disbelieve the postulate that pancreas lipase is an 
early marker for exocrine pancreatic insufficiency. They dispute that reason for early 
decrease of lipase activity is the result of its instability. Nevertheless, a fast analysis 
procedure is less vulnerable. Therefore, we established rapid analyses at our unit. As 
fatty malabsorption plays an important role in the diagnoses of exocrine pancreatic 
insufficiency, we think it is wise to have the possibility to measure the labile enzyme. 
A serious limitation of automation of measurement of bicarbonate concentration and 
enzyme activity in duodenal juice is the fact that no commercially available 
spectrophotometric auto analyser has certification for analyses in duodenal juice. 
However, our approach to compare two methods is the gold standard used in 
laboratory chemistry, when certifying measurements of parameters in blood, plasma, 
serum and urine for certification of auto analysers. We argue, the same methodology 
is appropriate for evaluating duodenal juice.  
Another weakness is the need for standard curves in the old methods for enzyme 
activity analyses. Technically speaking, when using the old methods, results are 
dependent on the actual standard solution with its standard curve. When storage time 
is over, production of a new standard solution with a new standard curve is necessary. 
Different standard curves can never be the same. The consequence is that comparison 
of the series using new standard solutions with the previous is not exactly possible. 
We think therefore that the use of automated measurement overcomes this serious 
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We have shown that simplification of direct pancreas function testing is possible.  
Shortening the invasive procedure to a total of 20 min gastroscopy makes it less 
uncomfortable for patient. Additionally, it does not exceed consultation time to a 
large extent in a busy endoscopic unit, leading to balance between economic aspects 
and extraordinary information for the clinician. We demonstrate that bicarbonate 
concentration in duodenal juice after secretin stimulation is a more precise parameter 
for exocrine pancreatic function than FE1, an indirect pancreas function test. 
Consecutively, identification of patients with mild CP succeeds better by measuring 
bicarbonate than with FE1when using a multimodal score including clinical 
information, imaging and pancreas function testing, the Layer (Mayo) score. By 
replacing the manual, time consuming multistep analysing procedures with automatic 
measurement with the same excellent accuracy, abolishes the need for specialized 
laboratory personal and can be performed in any basic laboratory. 
We have demonstrated that a three-step approach, with simplification of patient 
related procedure, pre-analytic preparation and automatized measurement of 
ingredients in duodenal juice, paves the way for implementation of direct pancreas 
function testing in clinical routine. The thought to use it at every hospital-based units 
with basic endoscopy and laboratory services is seductive. Most tertiary centres 
perform all studies on exocrine pancreatic function, CP and its aetiology. Therefore, 
generalizing of results may be a pitfall as non-tertiary centre units may underestimate 
exocrine pancreatic insufficiency and CP. Simplification of direct pancreas function 





7. Future Perspectives 
By optimizing the short endoscopic secretin test, we intend to unravel the secret of 
early exocrine pancreatic insufficiency. For this purpose, especially automation of 
lipase measurement is an important tool, as some authors regard the decrease in 
secretion of this enzyme earlier than decrease of amylase and proteases(241). A 
multimodal approach with analyses of all enzymes and other ingredients exploring 
genome, proteome and microbiome in duodenal juice could fill the gap.  
The clinical milieu at our location can offer a broad spectre in the diagnoses of 
pancreatitis, its causes and consequences. Formalized collaboration of different 
specialties could give a synergistic effect in diagnosing, treatment and follow-up of 
patients: 
1. Paediatric gastroenterologists and specialists in diabetes and genetics, diagnose 
patients with inborn errors, diabetes type III, and new genetic variants like MODY 5 
and 8 and CEL-MODY diabetes beside mutations in PRSS1, SPINK, CTRC and 
CFTR.  
2. Radiologists contribute substantially in the diagnostic evaluation of CP by 
performing morphologic and functional imaging with CT, MRI, MRCP and sMRCP.  
3. Gastroenterologists offer transabdominal and endoscopic ultrasonography with 
therapeutic options and direct pancreas function testing. Structured long-time follow-
up in the outpatient clinic is the guarantee to identify patients in risk for 
complications. Thus – early intervention is possible.  
4. Broad collaboration with surgeons and especially early diagnosis in case of 
malignancy can lead to a curative treatment of pancreatic cancer. Additionally, early 
operative treatment and ERCP related interventions minimize irreversible disease. 
Good clinical work-up is one of premises for good clinical science. With formalized a 
closer, interdisciplinary collaboration between the milieus as described above, 
clinical research could give essential impact.  
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We would like that different national or international centres could evaluate our short 
endoscopic secretin test.  To our knowledge, a direct pancreas function test is not 
practiced in any other Scandinavian country. To date there is no common direct 
function test worldwide. Thus, our short endoscopic Secretin test may open for 
multicentre studies. Duodenal juice after Secretin stimulation could be analysed for 
more than the known markers for exocrine pancreatic insufficiency. Proteomic, 
genetics or cancer specific markers may be of interest. If stored in a biobank, analyses 
of to date not known markers can be possible in the future. 
Faecal fat is not only interesting in a diagnostic setting, but also in the follow-up of 
patients, especially, when enzyme supplementation is not as effective as expected. An 
alternative test for quantification of faecal fat without collecting faeces and chemical 
analyses could make the procedure repeatable. MRI may be a possibility. Since 
Dixon found a method to differentiate fat and water, quantification of fat of all 
anatomic structures in the body got possible(242). Tremendous evolution of MRI 
techniques modified this method and today MR spectroscopy can differentiate 
between different types of fat (242;243). 
Transabdominal ultrasonography is inexpensive, convenient for the patient and can 
be repeated many times without complications, compared to all other imaging 
modalities often with radiation.  
As classification of CP in all its facets is only sufficient with a multimodal approach, 
we established a patient database. It enables structured and individualized follow-up 
with detection of CP complications in an early state. To date, we have included more 
than 120 patients with CP. Thus – in a few patients - diagnosis of malignant processes 
at an early state was possible and subsequently radical curative therapy led to 
survival. Furthermore, nutritional state, elimination of reversible risk factors and 
patient compliance improved in many patients. Our follow-up registration was 
integrated with a broader network, leading to the founding of the Scandinavian Baltic 
Database for CP, which is based on a multimodal diagnostic approach, the M-
ANNHEIM score. 
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The Scandinavian Baltic database also opens for research in epidemiology. 
Furthermore, the database reveals different clinical approaches in the participating 
countries and may thus lead to common and improved standards in diagnosing and 
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Short endoscopic secretin test
Bicarbonate
a b s t r a c t
Objectives: We have recently evaluated a short endoscopic secretin test for exocrine pancreatic function.
Bicarbonate concentration in duodenal juice is an important parameter in this test. Measurement of
bicarbonate by back titration as the gold standard method is time consuming, expensive and technically
difficult, thus a simplified method is warranted. We aimed to evaluate an automated spectrophotometric
method in samples spanning the effective range of bicarbonate concentrations in duodenal juice. We also
evaluated if freezing of samples before analyses would affect its results.
Methods: Patients routinely examined with short endoscopic secretin test suspected to have decreased
pancreatic function of various reasons were included. Bicarbonate in duodenal juice was quantified by
back titration and automatic spectrophotometry. Both fresh and thawed samples were analysed
spectrophotometrically.
Results: 177 samples from 71 patients were analysed. Correlation coefficient of all measurements was
r ¼ 0.98 (p < 0.001). Correlation coefficient of fresh versus frozen samples conducted with automatic
spectrophotometry (n ¼ 25): r ¼ 0.96 (p < 0.001)
Conclusions: The measurement of bicarbonate in fresh and thawed samples by automatic spectropho-
tometrical analysis correlates excellent with the back titration gold standard. This is a major simplifi-
cation of direct pancreas function testing, and allows a wider distribution of bicarbonate testing in
duodenal juice. Extreme values for Bicarbonate concentration achieved by the autoanalyser method have
to be interpreted with caution.
Copyright © 2016, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Introduction
Direct pancreas function testing (DPFT) is invasive and thereby
challenging. Used on correct indication it adds useful information
in exocrine pancreatic function testing. The test probably serves
best as a second line test in situations where primary tests, as faecal
elastase 1, are insufficient. DPFT can discriminate primary from
secondary pancreatic dysfunction [1,2]. Furthermore, direct tests
may prove useful in detecting early exocrine dysfunction, before
development of clinical obvious pancreatic exocrine insufficiency.
In our short endoscopic secretin test (short EST), duodenal juice
aspiration is performed in the period from 30 to 45 min after
secretin stimulation, in the plateau phase of duodenal bicarbonate
concentration. The whole endoscopic procedure, including a diag-
nostic gastroscopy, lasts normally not longer than 20 min [1e3],
hence overcoming some of the disadvantages of the time-
Abbreviations: DPFT, direct pancreas function testing; MDH, malatdehy-
drogenase; PEPC, phosphoenolpyruvate carboxylase.
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consuming and cumbersome tube based tests [3e7]. To distinguish
pancreatic exocrine failure from sufficient pancreas function a cut
off of 80 mmol/L bicarbonate concentration in duodenal juice is
generally accepted. Beneficial information about pancreatic
exocrine insufficiency (PEI) can be obtained in a variety of patients
with chronic pancreatitis, diabetes, cystic fibrosis, celiac disease.
We have used our short EST to evaluate exocrine pancreatic func-
tion in patients with chronic pancreatitis, cystic fibrosis and dia-
betes [3,8e13].
Back titration has long been considered the gold standard for
duodenal bicarbonate measurements [14,15]. This analysis is time
consuming (minimum 2 h) and technically difficult, hence being
expensive and vulnerable in routine diagnostics. As a conse-
quence, only a few specialised or research centres perform this
test today. Furthermore, back titration requires minimum 0.5 mL
of duodenal juice. Such volumes are sometimes difficult to obtain
from patients with severe ductal failure. In contrast, the auto-
analyser used in this study requires only a few microlitres of
duodenal juice and a short analysing time of 7 min. At present,
autoanalysers are certified to quantify ingredients in blood or
urine but not in duodenal juice. However, some earlier small
studies have demonstrated a good correlation between auto-
analysers and the back titration method [16,17] Automation of
bicarbonate analyses is required to simplify short EST, but the
method still needs further validation to replace back titration.
Daily routine in a busy medical institution makes immediate an-
alyses of duodenal juice to a challenge, and instant freezing of
samples could be an option for institutions sending samples for
analyses elsewhere.
In this study, we aimed to demonstrate the accuracy of an
automated spectrophotometric method compared to back titra-
tion when analysing bicarbonate in duodenal juice. Additionally,




The use of samples from short EST in the following projects was
approved by the local ethical committee: Chronic pancreatitis or
other causes of abdominal pain (approval no. 3.2008.2516), cystic
fibrosis (approval no.: 2010/2857-7) and celiac disease (approval
no. 2011/1592). Short EST of these patients was performed between
September 2012 and October 2014. Samples were chosen at
random for comparison of back titration and automated spec-
trometry. Three consecutive aliquots of duodenal juice with
different bicarbonate concentrations are collected in 15 min during
the short EST, hence 1 to 3 samples per patient could be analysed.
Short endoscopic secretin test
Secretin was administered intravenous at a dose of 1 CU per kg
bodyweight, maximum 70 CU. Gastroscopy started 25 min after
secretin administration. A diagnostic gastroscopy was initially
performed to identify or exclude other pathological findings. All
gastric juice was aspirated and discharged. After 30 min the tip of
the endoscope was placed distal to the papilla Vateri. Duodenal
juice was aspirated in three 5 min sequences. The procedure is
illustrated in Fig. 1 and described in detail elsewhere [3].
Handling of duodenal juice before analysis
ThepHandvolume of each samplewasmeasured.Duodenal juice
with pH < 6 was discarded due to probable pollution from gastric
juice. One aliquot of duodenal juice from each sampling period was
immediately placed on ice and bicarbonate concentration was
immediately analysed using back titration and automated analysis.
Otherwise samples were frozen to 196 C. In the experiment
Fig. 1. Short endoscopic pancreas function testing (EST): 25 min after injection of secretin (1 CU/kg bodyweight, max 70 CU) an upper endoscopy was started. During the first 5 min
a diagnostic gastroscopy was carried out. All juice from stomach and duodenum was discharged. Thereafter the tip of the endoscope was placed below the papilla for 15 min;
duodenal juice was collected in three aliquots of 5 min. The intervention requires only 20 min.
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comparing fresh and frozen samples, storage temperature
was80 C before analyses with automated spectrophotometry.
Analysis of bicarbonate in duodenal juice by back titration
The principles of back titration are described elsewhere [14].
The back titration method for bicarbonate analyses in detail:
Before analyses, pH was measured. Ideally 1 mL of duodenal
juice was needed to perform analyses but down to 0.5 mL was
accepted. If the volume of duodenal juice was <1 mL, the sample
was diluted to 1 mL using 0.9% NaCl. First, the pH of the sample was
analysed. To acidify the sample, 1.5 mL of 0.1 N HCl was added, and
the reaction between bicarbonate and HCl produced NaCl, H2O and
CO2. The CO2 (g) was evacuated by stirring the sample until pH was
stable. Next, the solution was titrated (“back titrated”) with 0.1 N
NaOH until the original pH value was achieved. Based on the vol-
ume of NaOH used, the bicarbonate concentration in the duodenal
juice was calculated using the formula.
(1000  (0.1 mol/L HCl  1.5 mL 0.1 mol/L HCl  0.1 mol/L
NaOH  Y mL 0.1 mol/L NaOH))/1 mL sample volume. Samples
were analysed in parallels.
Automated measurement (spectrophotometry)
For automated analyses, the spectrophotometer COBAS® c111
(Roche Diagnostics GmbH; D-68298 Mannheim; Germany; www.
roche.com) and the appropriate kit for measuring bicarbonate
(CO2-L Bicarbonate liquid, Roche Diagnostics AG, CH-6343 Rotkreuz,
Switzerland; www.roche-diagnostics.ch) were used. Analyses were
performed using 15 mL of duodenal juice dilutedwith 30 mL 0.9%NaCl
in water before it is pipetted by the instrument and added the start
reagent containing phosphoenolpyruvate (40 mmol/L), NADH
analogue (2.0mmol/L), porcinemalatdehydrogenase (314.3 ukat/
L) and phosphoenolpyruvate carboxylase (30.8 ukat/L).
The principle of the test is as follows: Bicarbonate in the samples
reacts with phosphoenolpyruvate in the presence of phospho-
enolpyruvate carboxylase (PEPC), to produce oxaloacetate and
phosphate. One hydrogen from a NADH analogue is transferred to
oxaloacetate using porcine malatdehydrogenase (MDH) to produce
malate and an NADþ analogue. The consumption of NADH results in
a decreased absorbance at 409 nm, proportional to the bicarbonate
concentration in the sample.
Statistical methods
Difference of groups was tested by t-test. Normality was tested
by the ShapiroeWilk test, andwhen it failed aManneWhitney rank
sum test was run. Correlation was calculated with Pearson test,
agreement with Bland Altman plot [18,19]. Adjustment was done by
linear regression. ROC curves were drawn to evaluate sensitivity
and specificity of spectrophotometry compared to gold standard
back titration. A 5% level of statistical significance was used. Soft-
wares used were ACCESS, EXCEL (Microsoft Office, Redmond WA,
USA), and SigmaPlot 12 (Systat Software Inc., San Jose, CA, USA).
Results
177 randomly chosen samples analysed by back titration and
automated spectrophotometry
In the time period of the study short EST was performed in 94
patients and 257 samples of duodenal juice were obtained. 177
samples from 71 patients were chosen arbitrary and analysed by
both back titration and automated spectrophotometry. Pearson test
showed an excellent correlation of all measurements with a coef-
ficient of r¼ 0.98, p < 0.001 (Fig. 2a). We performed supplementary
a Bland Altman plot to further explore the agreement over the
whole range: Mean difference (bias) was4.4 with a 95% CI of5.5
to 3.2. Agreement was excellent around the cut-off of 80 mmol/L
but weak in extreme values: Compared to back titration as gold
standard, the results from the autoanalyser showed higher levels
for very low concentrations of bicarbonate, and lower levels for
very high levels of bicarbonate (Fig. 2b). In a clinical setting, bi-
carbonate concentration of 80 mmol/L is used to differentiate be-
tween normal and insufficient ductal pancreatic function. Using
back titration as gold standard, sensitivity in spectrophotometry
was 97%, specificity 92% (AUC 0.99, p < 0.001). This implies that
automated spectrophotometry can discriminate between PEI and
non-PEI compared to back titration (Fig. 2c). Due to lack of agree-
ment in the range of high and low values of bicarbonate concen-
tration we calculated the following correction factor from linear
regression: [HCO3] back titration ¼ 7172 þ (1137*[HCO3] auto-
analyser) (mmol/L). When we recalculated the results using this
correlation factor we got the following results: Correlation coeffi-
cient of all measurements was r¼ 0.98, p < 0.001. Linear regression
did not change the excellent correlation (Fig. 2d). Bland Altman
plot: Mean difference was 0.03 with a 95% CI 1 to 1. Adjustment
by linear regression produced better agreement in extreme values
(Fig. 2e). Sensitivity and specificity with a cut-off of 80 mmol/L
using back titration as gold standard: sensitivity in spectropho-
tometry was 94%, specificity 94% (AUC 0.99, p < 0.001). ROC ana-
lyses show no difference in AUC after mathematical correction in
the identification of PEI.
25 pairs of fresh and frozen samples analysed by automated
spectrophotometry
Twenty-five samples from 9 patients were randomly chosen. In
all measurements correlation after Pearson was excellent with a
coefficient of r ¼ 0.96 with p < 0.001 (Fig. 3). The agreement
evaluated by the Bland Altman Plot was very good: Mean difference
was 1.3 with a 95% CI of e 5.1 to 2.6. There was no bias in extreme
values. Using the analysis of fresh samples as gold standard a ROC
curve for the measurement of frozen samples for a cut-off of
80 mmol/L bicarbonate was drawn. Sensitivity and specificity was
100% (AUC 1; p < 0.001). Storing samples at 80 C does not in-
fluence differentiation between PEI and non-PEI. Correlation and
agreement between the pairs of fresh and frozen samples are
excellent.
Standard solutions measured by back titration and
spectrophotometric autoanalyser
A series of 7 standard solutions with bicarbonate concentrations
of 20, 40, 60, 80, 100, 120, 140 mmol/L were analysed by back
titration and spectrophotometric autoanalyser. Pearson test in back
titration showed ideal correlation with a coefficient of 1 p < 0.001
(Fig. 4a). Bland Altman Plot pointed out nearly ideal agreement:
Mean difference was 0.4 with a 95% CI of 0.6 to 0.3. Also with
the spectrophotometric autoanalyser method an ideal correlation
factor of 1 with p < 0.001 could be reached (Fig. 4b). Evaluation
using the Bland Altman method revealed a bias analogue to
experiment I: In higher bicarbonate concentrations the difference
between standard solution and results by spectrophotometric
autoanalyser enlarges. Mean difference was 3.2 with a 95% CI
of 5.5 to 0.9 (Fig. 4c).
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Fig. 2. Correlation and agreement evaluated by measuring Bicarbonate in duodenal juice with back titration (BT) or autoanalyser (AA). Sensitivity and specificity of spectropho-
tometry at a cut-off point of 80 mmol/L. Back titration is the gold standard. A cut-off point of 80 mmol/L is generally accepted to discriminate insufficient from sufficient ductal
pancreatic function. N ¼ 177. a: Excellent correlation between the two methods (r ¼ 0.98; p < 0.001). b: Agreement between the two methods, excellent around the cut-off point of
80 mmol/L but weak in extreme values: In relation to back titration, autoanalyser measures in very low bicarbonate concentrations for high and in very high bicarbonate con-
centrations for low. We used therefore linear regression for correction: BT ¼ 7.172 þ (1.137*AA). c: Evaluation of the cut-off point of 80 mmol/L: Using ROC analyses with back
F. Erchinger et al. / Pancreatology 16 (2016) 231e237234
Discussion
In this study, we demonstrate that automated spectrophoto-
metric measurement of bicarbonate in duodenal juice correlates
excellent to analysis by the gold standard back titration method.
Although the back titration method on standard solutions per-
formed better than the spectrophotometric method, automated
measurement discriminated sufficient from insufficient pancreatic
function with good accuracy. Secondly, we also demonstrated that
freezing and thawing did not influence the spectrophotometric
result.
Changing from the gold standard back titration method to
automated spectrophotometry presents an important simplifica-
tion of the duodenal juice measurement. The excellent correlation
and agreement around the generally accepted cut-off value for
pancreatic exocrine failure makes it possible to replace the
expensive and cumbersome back titrationmethod by an automated
test which can be run in common, basic laboratory services.
Our results are comparable to earlier small studies using an
autoanalyser [16,17,20]. The present study comprises a larger
number of samples over the whole physiological and pathophysi-
ological range of bicarbonate concentration, thus adding informa-
tion on reduced agreement in the lower and the higher
concentration ranges. One possible explanation is that the high and
low range measurements are a result of false measurements.
However the same effect demonstrated in the standard solutions
argue against this possibility. Over the range to higher bicarbonate
concentrations the difference between standard solution and re-
sults by spectrophotometric autoanalyser enlarges. Back titration
did not show this phenomenon. A possible explanation is the
enzyme dependence in the autoanalyser method. Optimum pH of
Phosphoenolpyruvate carboxylase (PEPC) is 8e9 [21] and optimum
pH for malatdehydrogenase (MDH) is 7.4 (NADH —> NAD) [22]. We
assume that pH in extreme bicarbonate concentration is outside
the range of optimum pH of malatdehydrogenase. This would in-
fluence the consumption of NADH analogue and consecutively the
absorbance of light at 409 nm leading to false measures in extreme
bicarbonate concentrations.
Additionally, in both back titration and autoanalyser methods,
dilution with NaCl 0.9% is substantial. Producers of NaCl 0.9%
describe a range of pH between 4 and 7 at 20 C (106404 j Sodium
chloride, Merck Millipore Corporation. Merck KGaA, Darmstadt,
Germany). Our measures on different batch numbers revealed a pH
between 5.35 and 5.93. For this reasonwe analysed a small series of
duodenal juice with autoanalyser and diluted with either buffer or
NaCl; no difference was found. This indicates that results are not
influenced by NaCl 0.9%, or buffer. Also other studies have
demonstrated inferior agreement in bicarbonate values over
100 mmol/L. In these studies deionised water was used for dilution
[17]. A solution to minimise bias in extreme low or high levels of
bicarbonate concentration could be different dilution procedures.
Explanations by chemistry are not sufficient and lead to new
questions without answers. The size of our study using 177 samples
with values distributed over the effective range, from very low to
high bicarbonate concentrations made it possible to calculate a
correction factor with the linear regression. In practice very low or
very high concentrations of bicarbonate are not as interesting as the
range between 60 and 100mmol/L. Regardless of the demonstrated
weaknesses in the agreement in the lower and the higher range, we
demonstrate that this does not has substantial influence on the
overall accuracy of the test. The use of a correlation factor is
probably not necessary in clinical practice, but it implies that cli-
nicians are aware of this fact.
The size of the samples over the whole effective range may
explain that we can show the bias in the higher and lower values.
This may explain that the bias in the lower values is not shown by
other authors [16,17].
The amount of duodenal juice in a 5 min aliquot varies between
0 mL (dry tap) and 10 mL. In average we suctioned 2e5 mL per
aliquot. In severe pancreatic exocrine insufficiency (PEI) the
amount of duodenal juice is very poor. Bicarbonate analysis with
back titration needs minimum 0.5 mL of duodenal juice. Conse-
quently smaller amounts cannot be analysed with this method. In
contrast, we performed the spectrophotometric method with only
15 ml. If necessary this method allows measuring a lower quantum
of juice. The smaller volume requirement in the spectrophoto-
metric analysis increases the possibility to analyse duodenal bi-
carbonate in all patients.
Limitations of the study
Most limitations of the study can be found in the handling and
contents of the specimen. Samples were not centrifuged; consec-
utively pollution from debris or bloodmight affect the results of the
analyses. On the other hand, we excluded obviously polluted
samples and both methods will equally be affected.
For practical reasons in the sampling of juice from a large
number of patients, frozen samples were stored up to 197 days
at 196 C before analysis. There are no data about long-term
storage of samples at 196 C and its possible influence on bicar-
bonate results. We evaluated bicarbonate concentrations in cohorts
titration as gold standard. Automated spectrophotometric method is nearly as good as back titration. d: After the linear regression there was no change of correlation after
correction (r ¼ 0.98; p < 0.001), but the regression line is very close to the equality line. e: Bias is corrected; no deviation of high and low values is shown. Good agreement over the
whole range was reached.
Fig. 3. Correlation and agreement of 25 samples analysed by autoanalyser under two
conditions: 1) as fresh sample immediately after DPFT, 2) as frozen and thawed
samples: excellent correlation (R ¼ 0.96; p < 0.001).
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differentiated by storage time. No significant differences in corre-
lationwere shown. Therewas acceptable agreement up to 120 days.
In experiment II, samples were frozen at minus 80 C. As shown
there was excellent correlation and agreement with fresh samples.
This opens for storing duodenal juice in institutions without pos-
sibility of snap freezing to 196 C.
Differentiations in physiological contents of the aspirated
specimens might influence the results. The dye of aspirates of
duodenal juice varied from colourless to all grades of yellow sug-
gesting different contaminationwith biliary juice. Biliary acids may
influence activity of enzymes used in the spectrophotometric
method. However we think that this is negligible because back
titration is a chemical method without enzymes and has excellent
correlation and agreement to the spectrophotometric method in
the range of interest.
Conclusion
Endoscopic secretin-stimulated pancreas function testing has
not reached widespread distribution due to the invasive nature and
the complexity of the analysing procedures. Easy accessible, simple
and cost-effective indirect tests like faecal elastase 1 will probably
still be the first line or screening tests. Nevertheless, invasive direct
tests have a place in the second line testing due to the well-known
pitfalls in the simpler tests. Back titration as old gold standard is
time consuming and cumbersome. The validation of an automated
Fig. 4. 7 samples of standard solutions with bicarbonate concentrations (mmol/L) of 20, 40, 60, 80, 100, 120, 140 measured by back titration and spectrophotometric autoanalyser. a)
Equality of standard solution and back titration (r ¼ 1, p < 0.001). b) Equality of standard solution and autoanalyser (r ¼ 1, p < 0.001). c) Bland Altman Plot unmasks a proportional
bias: over the range to higher bicarbonate concentrations the difference between standard solution and results by spectrophotometric autoanalyser enlarges.
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spectrophotometric analysis of bicarbonate in duodenal juice rep-
resents a significant simplification of the DPFT. We argue that
simplifications of testing and analysis make standardisation of
DPFT within reach in the years to come. It will be possible to
perform DPFT globally in any health care institution with an
endoscopy unit and basic laboratory services.
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